Biotech NewsOcugen Announces FDA Clinical Hold Removal for Phase 2/3 COVAXIN (BBV152) Clinical Trial BioTech Health XMay 23, 2022 Biotechnology company Ocugen, Inc. (NASDAQ: OCGN) announced today that the U.S. Food and Drug Administration (FDA) has removed… 0 Shares 0 0 0 0 0 0 0
